Poziotinib’s Shift Of Focus To HER2 May Increase Approval Chances

Potential First-Line Therapy

 
• By Jung Won Shin
  
positive
No Specific Approved NSCLS Therapy So Far For HER2 Exon 20 Insertion Mutation • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D